EUCTR2014-003968-20-IT进行中（未招募）1 期
A phase 2, multicentre, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes - Ladarixin in diabetes onset
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Male and female patients aged 18-45 years, inclusive;
- •2.New-onset T1D (randomization within 100 days from 1st insulin administration);
- •3.Positive for at least one diabetes-related auto-antibody (anti-GAD; IAA, if obtained within 10 days of the onset of insulin therapy; IA-2 antibody; ZnT8);
- •4.Require, or has required at some time, insulin, with the exclusion of patients taking twice daily pre-mixed insulin or on insulin pump;
- •5.Residual ß-cell function as per peak stimulated (MMTT) C-peptide level >0.6ng/mL (0.2nmol/L); MMTT should not be performed within one week of resolution of a diabetic ketoacidosis event;
- •6.Patient able to comply with all protocol procedures for the duration of the study, including scheduled follow-up visits and examinations;
- •7.Patients who have given written informed consent prior of any study-related procedure not part of standard medical care;
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 72
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patients taking twice daily pre-mixed insulin or on insulin pump
- •2.Any other chronic disease, including type 2 diabetes, apart from autoimmune hypothyroidism requiring thyroid hormone replacement only; patients with severe (myxedema) disease potentially requiring immunosuppressive therapy will be excluded;
- •3.Moderate to severe renal impairment as per calculated creatinine clearance (CLcr) < 60 mL/min according to the Cockcroft-Gault formula (Cockcroft-Gault , 1976);
- •4.Hepatic dysfunction defined by increased ALT/AST > 3 x upper limit of normal (ULN) and increased total bilirubin > 3 mg/dL [>51.3 µmol/L];
- •5.Hypoalbuminemia defined as serum albumin < 3 g/dL;
- •6.QTcF > 470 msec;
- •7.Complete Left Bundle Branch Block (LBBB), atrio-ventricular block (mobitz II 2nd degree or 2:1 atrio-ventricular block), complete heart block;
- •8.Electronic pacemaker positioned or implanted defibrillator;
- •9.History of significant cardiovascular disease;
- •10.Known hypersensitivity to non-steroidal antiinflammatory drugs;
- •11.Concomitant treatment with phenytoin, warfarin, sulphanylurea hypoglycemics (e.g. tolbutamide, glipizide, glibenclamide/glyburide, glimepiride, nateglinide) and high dose of amitriptyline (> 50 mg/day);
- •12.Previous (within 2 weeks prior to randomization) and concomitant treatment with metformin, sulfonylureas, glinides, thiazolidinediones, exenatide, liraglutide, DPP-IV inhibitors or amylin, or any medications known to influence glucose tolerance (e.g. ß-blockers, angiotensin-converting enzyme inhibitors, interferons, quinidine antimalarial drugs, lithium, niacin, etc.);
- •13.Past (within 1 month prior to randomization) or current administration of any immunosuppressive medications (including oral, inhaled or systemically injected steroids) and use of any investigational agents, including any agents that impact the immune response or the cytokine system;
- •14.Pregnant or breast feeding women. Unwillingness to use effective contraceptive measures up to 2 months after the end of study drug administration (females and males).
研究者
相似试验
进行中（未招募）
1 期
A study to assess the efficacy and safety of oral ladarixin given 400 mg twice a day in patients with new-onset type 1 diabetesnew onset type 1 diabetesMedDRA version: 20.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0 Level: LLT Classification code 10012608 Term: Diabetes mellitus insulin-dependent System Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0 Level: HLT Classification code 10012602 Term: Diabetes mellitus (incl subtypes) System Organ Class: 100000004860MedDRA version: 20.0 Level: PT Classification code 10012601 Term: Diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2014-003968-20-DEDompé farmaceutici s.p.a.72
进行中（未招募）
1 期
A study to assess the efficacy and safety of oral ladarixin given 400 mg twice a day in patients with new-onset type 1 diabetesnew onset type 1 diabetesMedDRA version: 18.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 18.1 Level: LLT Classification code 10012608 Term: Diabetes mellitus insulin-dependent System Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 18.1 Level: HLT Classification code 10012602 Term: Diabetes mellitus (incl subtypes) System Organ Class: 100000004860MedDRA version: 18.1 Level: PT Classification code 10012601 Term: Diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 18.1 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2014-003968-20-BEDompé farmaceutici s.p.a.72
进行中（未招募）
不适用
A phase 2, multi-centre, randomized, double-blind, placebo-controlled, parallel-group 3 arms pilot study to assess the efficacy, the safety and the pharmacokinetics of two treatment schedules of reparixin in the prevention of delayed graft function after kidney transplantation in high risk patients.EUCTR2005-001300-39-ITDOMPE s.p.a.72
进行中（未招募）
1 期
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetesew-onset Type 1 DiabetesMedDRA version: 21.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2020-002966-15-DEDompe farmaceutici s.p.a.75
进行中（未招募）
1 期
A phase 2 Dose-finding study of IMU-838 in patients with active Crohn’s diseaseCrohn’s disease (CD)MedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2018-001895-39-HRImmunic AG258